At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 430 enrolled
Drug / intervention
Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762] +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment
In Brief
A Phase 3 clinical trial evaluating Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762], Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762], and 1 other intervention for Cat Allergy. Completed, enrolled 430 participants.
Detailed Summary
The purpose of this study is to evaluate the continued effectiveness and safety of Cat-PAD in cat allergic subjects for up to five years after the start of administration of treatment. The study is an optional follow-up study to a phase III double-blind, placebo controlled, Cat-PAD study; no further investigational product is administered.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCat Allergy
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 2014
Enrollment StartFeb 2014
Primary CompletionMay 2017
TodayJul 2026
First PostedJan 20, 2014
Enrollment StartFeb 1, 2014
Primary CompletionMay 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 12.5 years ago
Interventions
Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762]drug
Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762]drug
Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]drug